文献速递消化系统肿瘤

肿瘤HER3 mRNA表达与帕尼单抗疗效的关联

Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer.
PubMed 文献 · JAMA Oncol · 2018-01-01

该研究为PICCOLO试验的前瞻性计划回顾性生物标志物分析,评估HER3 mRNA表达作为抗EGFR治疗预后和预测标志物的价值。在308例KRAS野生型晚期结直肠癌患者中,高HER3表达与帕尼单抗联合伊立替康的无进展生存期延长相关,且生物标志物与治疗交互作用显著。

要点

  • HER3高表达者中位PFS 8.2个月(联合组)vs 4.4个月(伊立替康组),HR 0.33。
  • HER3低表达者未从帕尼单抗联合治疗中获益,PFS HR 0.96。

核心结论

  • 高HER3表达可识别RAS野生型晚期结直肠癌中从帕尼单抗联合伊立替康治疗中显著获益的患者,PFS和OS的生物标志物-治疗交互作用均显著。

研究设计与样本

  • PICCOLO试验的前瞻性计划回顾性生物标志物研究,纳入308例KRAS野生型晚期结直肠癌患者(平均年龄61.6岁,193例男性),评估治疗前样本HER3 mRNA表达。

关键数值与推荐

  • 二分类模型以第66百分位为界划分HER3高表达与低表达。

临床怎么用

  • 高HER3表达可能有助于识别RAS野生型晚期结直肠癌中从帕尼单抗联合伊立替康治疗中显著获益的患者,具有潜在临床效用。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Epidermal growth factor receptor (EGFR) (HER1) signaling depends on ligand binding and dimerization with itself or other HER receptors. We previously showed in a randomized trial that high EGFR ligand expression is predictive of panitumumab benefit in advanced colorectal cancer. Tumor expression of HER3 may further refine the RAS wild-type (wt) population benefitting from anti-EGFR agents. OBJECTIVE: To examine HER3 messenger RNA expression as a prognostic and predictive biomarker for anti-EGFR therapy in a randomized clinical trial of panitumumab. DESIGN, SETTING, AND PARTICIPANTS: The study was a prospectively planned retrospective biomarker study of pretreatment samples from the PICCOLO trial that tested the addition of panitumumab to irinotecan therapy in patients with KRAS wt advanced colorectal cancer who experienced failure with prior fluoropyrimidine treatment. HER3 was assessed as a prognostic marker, then as a predictive biomarker in patients with RAS wt, first as a continuous variable and then as a binary (high vs low) variable. Relationship with MEK-AKT pathway mutations and EGFR ligands epiregulin and amphiregulin (EREG/AREG) were also assessed. MAIN OUTCOMES AND MEASURES: Primary end point was progression-free survival (PFS); secondary end points were response rate and overall survival (OS). RESULTS: In 308 patients (mean age at randomization, 61.6 years; 193 men) higher HER3 was weakly prognostic for OS (hazard ratio [HR] per 2-fold change, 0.91; 95% CI, 0.83-0.99; P = .04) but not PFS (HR, 0.93; 95% CI, 0.83-1.05; P = .25). Higher HER3 was predictive, being associated with prolonged PFS on irinotecan plus panitumumab (IrPan) (HR, 0.71; 95% CI, 0.61-0.82; P < .001), but not irinotecan (HR, 0.96; 95% CI, 0.82-1.13; P = .65) in patients with RAS wt, with significant interaction between biomarker and treatment (P = .001). Similar interaction was seen for OS (P = .004). In an exploratory binary model, dividing the population at the 66th percentile, HER3 was predictive of panitumumab benefit: in patients with high HER3 expression, median PFS was 8.2 months (IrPan) vs 4.4 months (irinotecan) (HR, 0.33; 95% CI, 0.19-0.58; P < .001). Patients with low HER3 expression gained no benefit in PFS: 3.3 months (IrPan) vs 4.3 months (irinotecan) (HR, 0.96; 95% CI, 0.67-1.38; P = .84), with significant interaction (P = .002). The binary model was also predictive for OS, with significant interaction (P = .01). Combining HER3 and ligand data, patients with HER3-high, AREG/EREG-high tumors gained markedly from panitumumab (PFS HR, 0.24; 95% CI, 0.11-0.51; P < .005 and OS HR, 0.36; 95% CI, 0.18-0.73; P = .004). Conversely, patients with HER3-low, AREG/EREG-low tumors did not benefit (PFS HR, 1.14; 95% CI, 0.73-1.79; P = .57 and OS HR, 1.44; 95% CI, 0.92-2.26; P = .11). CONCLUSIONS AND RELEVANCE: High HER3 expression identified patients with RAS wt who gained markedly from panitumumab, and those who did not, with statistically significant biomarker-treatment interactions for PFS and OS. This finding provides insight into the mechanism of anti-EGFR agents and is of potential clinical utility.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Seligmann JF, Hatch AJ, Richman SD, et al. Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer. JAMA Oncol. 2018. PMID: 29075780. doi:10.1001/jamaoncol.2017.3168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。